<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940602-2-00107</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Drug Enforcement Administration</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>Importation of Controlled Substances; Application</DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Pursuant to section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. <!-- PJG 0012 frnewline --> Therefore, in accordance with section 1311.42 of title 21, Code of Federal Regulations (CFR), notice is hereby given that on April 15, 1994, Radian Corporation, 8501 Mopac Blvd., P.O. Box 201088, Austin, Texas 78720, made application to the Drug Enforcement Administration to be registered as an importer of the basic classes of controlled substances listed below: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 2,L2,tp0,i1,s25,xs36 -->  <!-- PJG ITAG l=95 g=1 f=1 --> &blank; <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1&blank; <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Schedule <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Drug: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> Ibogaine (7260)  <!-- PJG 007 0104 intable --> I <!-- PJG 0012 frnewline --> Dihydromorphine (9145)  <!-- PJG 007 0104 intable --> I <!-- PJG 0012 frnewline --> Cocaine (9041)  <!-- PJG 007 0104 intable --> II <!-- PJG 0012 frnewline --> Codeine (9050)  <!-- PJG 007 0104 intable --> II <!-- PJG 0012 frnewline --> Dextropropoxyphene, bulk (non-dosage forms) (9273)  <!-- PJG 007 0104 intable --> II <!-- PJG 0012 frnewline --> Morphine (9300)  <!-- PJG 007 0104 intable --> II <!-- PJG 0012 frnewline --> Thebaine (9333)  <!-- PJG 007 0104 intable --> II <!-- PJG 0012 frnewline --> Oxymorphone (9652)  <!-- PJG 007 0104 intable --> II <!-- PJG /ITAG -->  </TABLE>  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> The firm plans to import deuterated material not currently available in the United States for manufacturing of exempt products. <!-- PJG 0012 frnewline --> Any manufacturer holding, or applying for, registration as a bulk manufacturer of this basic class of controlled substance may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.54 in such form as prescribed by 21 CFR 1316.47. <!-- PJG 0012 frnewline --> Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than July 5, 1994. <!-- PJG 0012 frnewline --> This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1311.42 (b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745&hyph;46 (September 23, 1975), all applicants for registration to import a basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42 (a), (b), (c), (d), (e), and (f) are satisfied. <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: May 23, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Gene R. Haislip, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;13397 Filed 6&hyph;1&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4410&hyph;09&hyph;M <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            